GENE ONLINE|News &
Opinion
Blog

2020-11-07| Asia-Pacific

Shionogi Accesses Ping An’s Database of 300 Million People in China to Design New Healthcare Services

by Tyler Chen
Share To

The pharmaceutical market in China is expected to reach 250 trillion yen in 2030, ranking second after the United States and most importantly displaying great potential for the healthcare supply chain.

Eying the tremendous healthcare data that can be collected in China, Japan-based drug maker Shionogi plans on accessing Ping An Insurance’s database that includes over 300 million people in China for the development of new drugs and healthcare services.

 

Advantages of Accessing Data in China

As Japan’s pharmaceutical company starting to work cross-industry and go digital, Shionogi allied with its China comrade by utilizing the wide range of healthcare data in China to target the actual needs of the consumers instead of randomly throwing out products to test the market. “We can’t answer the needs of patients and health care stakeholders by providing pharmaceutical products alone,” Teshirogi said.

What’s more, China would be a strategic place for Shionogi to build up new products because the laws of securing personal data are weaker than in Japan, therefore boosting possibilities for companies to try out new business models

Shionogi President Isao Teshirogi once said that “You can do things in China that you can’t do in Japan,” expressing that China is comparatively freer.

Furthermore, the alliance Shionogi works with is no amateur. Ping An is one of the largest financial service companies in the world, providing integrated financial services in 5 fields, including healthcare, auto services, real estate services, and smart city. Ping An not only ranked 7th in the Forbes Global 2000 list in 2020 also scored 29th on the Fortune Global 500 list in 2019.

 

Cooperation Since March

Strong ties between Shionogi and Ping An can be traced back to March 2020, where Shionogi sold 33.5 billion yen worth of shares to Ping An, positioning Ping An as the 7th biggest shareholder with 2%. In July 2020, Shionogi and Ping An launched joint ventures in Shanghai (Ping An-Shionogi) and Hong Kong (Ping An-Shionogi Hong Kong), aiming to tackle the increasing demand for healthcare services and innovative drugs with AI and new technology, fundamentally building up an ecosystem and platform in Asia.

By Tyler Chen

Related Article: Spotlight: Shionogi’s Big Bet on Tetra Therapeutics

References
  1. http://www.pingan.cn/tc/common/news/article/1595840405317.shtml
  2. http://www.pingan.cn/tc/common/news/article/1585556027098.shtml

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Moderna To Collaborate With Harbour BioMed On Nucleic Acid-Based Cancer Therapies
2022-11-14
35% of Americans May Avoid Seeking Care Due to Concerns Over Healthcare Prices
2022-10-31
Transforming Southern California Biotech Landscape: An Interview With SoCalBio CEO Ahmed Enany
2022-10-18
LATEST
Axsome’s AXS-05 Achieves Endpoints In Alzheimer’s Agitation Trial
2022-11-29
Spectrum to Cut 75% of Staff and NSCLC Program Following CLR
2022-11-28
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022-11-28
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
2022-11-28
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
2022-11-28
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!